GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Cocrystal Pharma Inc.
Cocrystal Pharma is a biotech company developing antiviral drugs. Its stock price is highly volatile, driven by news of clinical trials and outbreaks of diseases such as influenza and COVID-19, which drives interest in its developments.
Share prices of companies in the market segment - Pharma virus
Cocrystal Pharma is a biopharmaceutical company focused on developing antiviral drugs for the treatment of influenza, hepatitis C, norovirus, and other infections. We've categorized it as "Pharma: Viruses." The chart below shows how investors value companies in this important field.
Broad Market Index - GURU.Markets
Cocrystal Pharma is a biotech company developing antiviral drugs for the treatment of influenza, hepatitis C, and norovirus. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Cocrystal shares correlate with sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
COCP - Daily change in the company's share price Cocrystal Pharma Inc.
For Cocrystal Pharma, Inc., a company developing antiviral drugs, daily price changes are a measure of enormous volatility. This metric reflects extreme sensitivity to clinical trial data, especially in light of pandemic threats.
Daily change in the price of a set of shares in a market segment - Pharma virus
Cocrystal Pharma, Inc. is a biotech company. This chart highlights the sector's extreme volatility. Comparison with COCP, which focuses on antiviral drugs, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Cocrystal Pharma is a biotech company specializing in the development of antiviral drugs. Its research successes and failures cause sharp fluctuations in its stock price. This scientifically driven volatility is an important part of the varied pattern of movements in the overall stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Cocrystal Pharma Inc.
For Cocrystal Pharma, Inc., year-over-year performance is a story about antiviral drug development. Its 12-month market cap depends entirely on progress in clinical trials of its candidates for the treatment of influenza, hepatitis C, and norovirus. Success in any of these areas could be a fundamental breakthrough for the company.
Annual dynamics of market capitalization of the market segment - Pharma virus
Cocrystal Pharma, Inc. is a clinical-stage biotech developing antiviral drugs. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cocrystal Pharma is a bet on fighting viral threats. Its stock price rises during disease outbreaks or on news about progress in antiviral drug development. At other times, it may lag the market. Its chart is a story of anticipation for the next pandemic or scientific breakthrough.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Cocrystal Pharma Inc.
Cocrystal Pharma is a biotech company developing antiviral drugs. Its monthly performance is entirely dependent on progress in its clinical programs. News of trial results for its influenza, hepatitis, and coronavirus drugs are the main catalyst.
Monthly dynamics of market capitalization of the market segment - Pharma virus
Cocrystal Pharma is a biotechnology company focused on developing antiviral drugs for the treatment of diseases such as influenza, hepatitis C, and COVID-19. The chart below shows the overall dynamics in the pharmaceutical sector, where the need for new and effective antiviral agents remains extremely high.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shares of biotech companies developing antiviral drugs can explode on news of pandemics or successful trials. The chart below shows the general trends. Is Cocrystal Pharma moving at its own pace?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Cocrystal Pharma Inc.
Cocrystal, a biopharmaceutical company developing small-molecule antiviral drugs, is extremely sensitive to epidemiological news. Its weekly stock price is a strong reaction to clinical trial data and outbreaks of viral diseases such as influenza and norovirus.
Weekly dynamics of market capitalization of the market segment - Pharma virus
Cocrystal Pharma operates in the biotech sector, where shared technological breakthroughs and regulatory decisions impact everyone. The success of one company can boost the entire segment. The chart will show whether the market perceives COCP as a promising player in the fight against viruses or simply part of the mainstream.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
As a biotech company, Cocrystal Pharma, Inc. often ignores broader market trends. Its fate depends less on news about virus threats than on the state of the economy. The chart below clearly demonstrates how COCP shares can live a life of their own, separate from the broader market.
Market capitalization of the company, segment and market as a whole
COCP - Market capitalization of the company Cocrystal Pharma Inc.
Cocrystal Pharma's stock price is a focused bet on antiviral drugs. This company's market cap reflects investors' hopes for its developments against influenza, hepatitis, and norovirus. Its volatile dynamics reflect the market's assessment of its scientific data and the long, risky path to drug approval.
COCP - Share of the company's market capitalization Cocrystal Pharma Inc. within the market segment - Pharma virus
Cocrystal Pharma develops antiviral drugs for the treatment of influenza, hepatitis C, and norovirus. Its market share is based on its scientific platform. The chart shows how the market values its pipeline of candidates and its ability to develop new, effective drugs against common viral infections.
Market capitalization of the market segment - Pharma virus
Cocrystal Pharma develops small-molecule antiviral drugs, including those against influenza, hepatitis C, and norovirus. The chart below shows the pharmaceutical sector's market capitalization. This reflects the vital importance of finding new ways to combat common viral infections.
Market capitalization of all companies included in a broad market index - GURU.Markets
Cocrystal Pharma develops small-molecule drugs to treat viral diseases such as influenza and hepatitis C. Its market capitalization is a bet on its scientific platform. The chart below shows the economic weight of companies developing antiviral drugs.
Book value capitalization of the company, segment and market as a whole
COCP - Book value capitalization of the company Cocrystal Pharma Inc.
Cocrystal Pharma is based on a scientific platform for combating viruses. The company's book value reflects its patents for structural biology technology, which enables the rapid development of antiviral drugs (for influenza and hepatitis), and its R&D capital. The chart below shows the financial basis for this important scientific research.
COCP - Share of the company's book capitalization Cocrystal Pharma Inc. within the market segment - Pharma virus
Cocrystal Pharma, Inc., a biopharmaceutical company, focuses on R&D for antiviral drugs. Its laboratories are its primary physical asset. The S_BCap_Seg chart shows its small share of physical infrastructure.
Market segment balance sheet capitalization - Pharma virus
Cocrystal Pharma develops antiviral drugs. Its assets are scientific data and patents. The chart shows that its balance sheet is virtually devoid of tangible assets, which is typical for a biotech company focused on research and development.
Book value of all companies included in the broad market index - GURU.Markets
Cocrystal Pharma's assets comprise a platform for developing antiviral drugs. The company's book value reflects its R&D laboratories, structural biology equipment, and the rights to several candidate molecules. This material base is aimed at developing drugs for influenza, hepatitis C, and norovirus.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Cocrystal Pharma Inc.
Cocrystal Pharma develops antiviral drugs. Its book value represents R&D funding. Its market capitalization is a highly volatile bet on the success of its research and development efforts against viruses like influenza and norovirus.
Market to book capitalization ratio in a market segment - Pharma virus
Cocrystal Pharma develops antiviral drugs. Its value depends on the success of its clinical programs. The chart shows how market expectations for its development pipeline compare to its tangible assets.
Market to book capitalization ratio for the market as a whole
Cocrystal Pharma develops antiviral drugs. The company's value depends almost entirely on the success of its clinical trials. The chart shows how its market valuation reflects its belief in the company's scientific potential to develop effective treatments against viruses such as influenza and COVID-19.
Debts of the company, segment and market as a whole
COCP - Company debts Cocrystal Pharma Inc.
Cocrystal Pharma, a company developing antiviral drugs, uses debt to finance its research. This chart shows the capital raised for preclinical and clinical trials of its candidates against influenza viruses, hepatitis C, and coronaviruses.
Market segment debts - Pharma virus
Cocrystal Pharma is a biotech company developing antiviral drugs for the treatment of diseases such as influenza, hepatitis C, and COVID-19. Its financial future depends entirely on the success of clinical trials. This chart shows its financial reserves for continued R&D.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Cocrystal Pharma Inc.
Cocrystal Pharma is a biotech company focused on developing antiviral drugs. This chart shows whether it is raising debt financing. For a company working on flu or hepatitis drugs, debt can accelerate research, but failure in clinical trials will make servicing it extremely difficult.
Market segment debt to market segment book capitalization - Pharma virus
Cocrystal Pharma is a biotech company developing antiviral drugs. This chart for the biotech sector illustrates how the industry as a whole raises capital to fund lengthy and risky clinical trials. It helps assess the company's financial position in the context of the high costs typical of biotech.
Debt to book value of all companies in the market
Cocrystal Pharma is a biotech company focused on developing antiviral drugs. This chart, which shows the debt-to-book ratio of the entire market, is important for assessing the investment climate. The market's willingness to finance companies working on global health issues determines Cocrystal's ability to move forward.
P/E of the company, segment and market as a whole
P/E - Cocrystal Pharma Inc.
Cocrystal Pharma is developing antiviral drugs to treat diseases such as influenza, hepatitis C, and COVID-19. This chart reflects confidence in its scientific platform. Its dynamics are heavily dependent on news about clinical trials. Successful data could trigger a sharp increase, reflecting the huge potential market for effective antiviral agents.
P/E of the market segment - Pharma virus
Cocrystal Pharma, Inc. is a biotech company. This chart shows the average P/E for the biotech sector. Comparing the company's P/E to this benchmark allows us to understand how highly the market values its antiviral drug development platform compared to the average prospects of other biotech companies.
P/E of the market as a whole
Cocrystal Pharma is a biotech company focused on developing antiviral drugs for the treatment of diseases such as influenza, hepatitis C, and norovirus. This chart shows sentiment in the biotech sector. The company's valuation is highly sensitive to news about its clinical programs and viral outbreaks, which could increase interest in its developments.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Cocrystal Pharma Inc.
Cocrystal Pharma is a biopharmaceutical company focused on developing antiviral drugs. The chart shows future revenue expectations, which depend on the success of clinical trials of its candidates for influenza, hepatitis C, and norovirus.
%20P%2FE%20Cocrystal%20Pharma%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Cocrystal-Pharma-Inc.&v=1772574326241 "Chart of the company's future (projected) P/E Cocrystal Pharma Inc.")
Future (projected) P/E of the market segment - Pharma virus
Cocrystal Pharma is a clinical-stage company developing small-molecule antiviral drugs for the treatment of influenza, hepatitis C, and norovirus. This chart displays its expected future profitability, allowing us to assess how the market perceives its scientific platform and development pipeline.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-virus&v=1772574326266 "Future (projected) P/E graph of the market segment - Pharma virus")
Future (projected) P/E of the market as a whole
Cocrystal Pharma is a biotech company developing antiviral drugs, including those for the treatment of influenza and COVID-19. Its valuation is based on the company's success in clinical trials. The company's valuation is not tied to market forecasts, but is determined by scientific data and the need for new drugs.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772574326288 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Cocrystal Pharma Inc.
Cocrystal Pharma, Inc. is a biotechnology company developing antiviral drugs for the treatment of serious infections such as influenza, hepatitis C, and norovirus. Being in the clinical stage, it incurs significant R&D expenditures. This chart reflects investments in the development of new drugs to combat viral threats.
Profit of companies in the market segment - Pharma virus
Cocrystal Pharma, Inc. is a clinical-stage biopharmaceutical company using its platform to develop antiviral drugs for the treatment of influenza, hepatitis C, and norovirus. This chart shows the profitability of the antiviral segment. R&D costs impact current profitability, but its technology has the potential to lead to the development of effective drugs.
Overall market profit
Cocrystal Pharma is a biotechnology company focused on developing antiviral drugs. There is always a need for new drugs against influenza, hepatitis, and other viruses. This graph illustrates general economic cycles, while Cocrystal's success depends on scientific breakthroughs and the preparedness of healthcare systems for new viral threats.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Cocrystal Pharma Inc.
Cocrystal Pharma is a biotech company focused on developing antiviral drugs for the treatment of influenza, hepatitis C, and norovirus. This chart reflects analysts' future earnings expectations, based on the potential of its scientific platform. It demonstrates the market's confidence in the company's ability to develop effective treatments against common viral infections.
%20profit%20of%20the%20company%20Cocrystal%20Pharma%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Cocrystal-Pharma-Inc.&v=1772574326369 "Graph of future (projected) profit of the company Cocrystal Pharma Inc.")
Future (predicted) profit of companies in the market segment - Pharma virus
Cocrystal Pharma, Inc. is a biotechnology company developing antiviral drugs for the treatment of influenza, hepatitis C, and norovirus. This chart shows profitability forecasts for the antiviral pharmaceutical segment. It reflects expectations for new treatments for viral infections, which remain a serious public health problem.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-virus&v=1772574326395 "Graph of future (predicted) profits of companies in a market segment - Pharma virus")
Future (predicted) profit of the market as a whole
Cocrystal Pharma develops antiviral drugs. For a biotech company in the research stage, the market profit forecast is important as an indicator of funding availability. During periods of economic optimism, investors are more willing to invest in risky biotech, which is vital for advancing their research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772574326431 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Cocrystal Pharma Inc.
Cocrystal Pharma, Inc. is a biotechnology company developing antiviral drugs. Currently in the clinical stage, it has no revenue. P/S will become key following successful clinical trials and market entry, especially given the increased focus on antiviral therapy.
P/S market segment - Pharma virus
Cocrystal Pharma, Inc. is a biotech company developing antiviral drugs for the treatment of influenza, hepatitis C, norovirus, and coronaviruses. Their platform enables the creation of small-molecule inhibitors. This chart shows how the market views their scientific approach and portfolio of antiviral candidates in light of the ongoing threat of pandemics.
P/S of the market as a whole
Cocrystal Pharma develops antiviral drugs for the treatment of influenza, hepatitis C, and norovirus. The company has no commercial revenue, and its valuation depends on the success of clinical trials. This chart, showing the estimated real revenue, highlights Cocrystal's high-risk bet on fighting viral infections.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Cocrystal Pharma Inc.
Cocrystal Pharma is a biopharmaceutical company developing antiviral drugs for the treatment of influenza, hepatitis C, norovirus, and coronaviruses. This chart reflects investor expectations for future revenue from its developments, betting on its ability to create effective treatments against these common viral threats.
%20P%2FS%20Cocrystal%20Pharma%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Cocrystal-Pharma-Inc.&v=1772574326550 "The graph of the company's future (projected) P/S Cocrystal Pharma Inc.")
Future (projected) P/S of the market segment - Pharma virus
Cocrystal Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing novel antiviral drugs for the treatment of influenza, hepatitis C, and norovirus. This chart shows how the market perceives the future potential of its pipeline, comparing it to other companies in the antiviral pharmaceutical sector.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20virus&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-virus&v=1772574326592 "Future (projected) P/S market segment graph - Pharma virus")
Future (projected) P/S of the market as a whole
Cocrystal Pharma is a biotech company specializing in the development of antiviral drugs. It uses a proprietary platform for structure-based drug design. This chart shows overall investor revenue forecasts, and COCP demonstrates how the pandemic has increased interest in technologies that could accelerate the development of new antiviral drugs.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772574326652 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Cocrystal Pharma Inc.
Cocrystal Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing antiviral drugs, including those for influenza and COVID-19. Because its products are in development, the company has no sales revenue. Any revenue shown in this chart may be from grants or partnerships.
Sales of companies in the market segment - Pharma virus
Cocrystal Pharma is a biotech company focused on developing antiviral drugs. Currently, its revenue, if any, may come from government contracts or partnerships. This chart provides an estimate of external financial support for its research.
Overall market sales
Cocrystal Pharma, Inc. is a biotechnology company focused on developing antiviral drugs. The need for such drugs can arise suddenly and is not dependent on economic cycles. This chart does not reflect the company's specific drivers, whose success depends on scientific breakthroughs and the epidemiological situation.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Cocrystal Pharma Inc.
Cocrystal Pharma is a biotech company developing antiviral drugs for the treatment of influenza, hepatitis C, and norovirus. Its revenue forecast depends on the success of clinical trials and partnerships. This chart shows analysts' speculative expectations for its antiviral pipeline.
%20sales%20of%20the%20company%20Cocrystal%20Pharma%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Cocrystal-Pharma-Inc.&v=1772574326746 "Schedule of future (projected) sales of the company Cocrystal Pharma Inc.")
Future (projected) sales of companies in the market segment - Pharma virus
Cocrystal Pharma is a biotechnology company focused on developing antiviral drugs. This chart shows projected revenues for this entire pharmaceutical segment. It helps assess how large and rapidly growing analysts see this market, which is especially relevant in light of global threats and crucial for assessing Cocrystal's potential.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-virus&v=1772574326798 "Schedule of future (projected) sales of companies in the market segment - Pharma virus")
Future (projected) sales of the market as a whole
Cocrystal Pharma is a biotechnology company developing antiviral drugs, including those for the treatment of influenza and COVID-19. Its success depends on the results of clinical trials and the epidemiological situation. This schedule of general market expectations influences government funding for infectious disease programs and the investment climate.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772574326823 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Cocrystal Pharma Inc.
Cocrystal Pharma is a biopharmaceutical company focused on developing antiviral drugs. This chart reflects its current status in clinical trials. It doesn't show revenue, but rather the amount of investment in developing new drugs for influenza, hepatitis C, and norovirus.
Market segment marginality - Pharma virus
Cocrystal Pharma, Inc. is a biotechnology company that uses its unique structure-based platform to discover and develop new antiviral drugs. This chart reflects the average profitability in the pharmaceutical sector. It helps assess the commercial potential of Cocrystal's developments for the treatment of viruses such as influenza and hepatitis C.
Market marginality as a whole
Cocrystal Pharma, Inc. is a biotechnology company developing antiviral drugs. This overall profitability chart is not relevant to its business, which becomes especially relevant during viral outbreaks and pandemics, when demand for effective medications is enormous.
Employees in the company, segment and market as a whole
Number of employees in the company Cocrystal Pharma Inc.
Cocrystal Pharma is a biopharmaceutical company focused on developing antiviral drugs. Its small scientific team is using its unique platform to develop drugs against influenza, hepatitis C, and norovirus. This chart shows the size of its focused R&D team in this important area of medicine.
Share of the company's employees Cocrystal Pharma Inc. within the market segment - Pharma virus
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral drugs. This chart illustrates its scientific expertise. It reflects the proportion of virologists and chemists working with Cocrystal to develop drugs against influenza, hepatitis C, and norovirus using its unique structural platform.
Number of employees in the market segment - Pharma virus
Cocrystal Pharma, Inc. is a biopharmaceutical company developing antiviral drugs. This chart shows employment in the viral pharmaceuticals sector. The growing number of scientists in this field reflects the ongoing threat of viral infections such as influenza and hepatitis and the need to develop new, more effective drugs.
Number of employees in the market as a whole
Cocrystal Pharma, Inc. is a biopharmaceutical company focused on developing antiviral drugs. The threat of viral pandemics drives ongoing research in this area. This chart shows overall employment, and these companies are at the forefront of science, working to develop effective defenses against viral threats.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Cocrystal Pharma Inc. (COCP)
Cocrystal Pharma, Inc. fights viral diseases. Its value is the potential of its scientific developments. This chart shows the enormous value the market places on each scientist searching for a cure for influenza or hepatitis. It's an estimate of intellectual capital and future patents.
%20of%20the%20company%20Cocrystal%20Pharma%20Inc.%20(COCP)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Cocrystal-Pharma-Inc.-COCP&v=1772574327048 "Chart of market capitalization per employee (in thousands of dollars) of the company Cocrystal Pharma Inc. (COCP)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma virus
Cocrystal Pharma develops antiviral drugs. In this biotech field, the market value per employee reflects investors' faith in its scientific platform. A high figure indicates high hopes for the development of effective drugs against influenza, hepatitis, and other viral infections.
%20by%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-virus&v=1772574327131 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma virus")
Market capitalization per employee (in thousands of dollars) for the overall market
Cocrystal Pharma is a biopharmaceutical company developing antiviral drugs. Interest in this field has been high since the pandemic. This chart reflects investor expectations for the ability of a small team of scientists to create new, effective treatments against influenza, norovirus, and other viral threats.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772574327230 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Cocrystal Pharma Inc. (COCP)
Cocrystal Pharma is a clinical-stage biotech company focused exclusively on developing antiviral drugs (for influenza, COVID, and norovirus). It's an R&D business. This negative graph shows how much capital is burned for each scientist working on these important drugs.
%20Chart%20Cocrystal%20Pharma%20Inc.%20(COCP)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Cocrystal-Pharma-Inc.-COCP&v=1772574327248 "Company Profit Per Employee (in thousands of dollars) Chart Cocrystal Pharma Inc. (COCP)")
Profit per employee (in thousands of dollars) in the market segment - Pharma virus
Cocrystal Pharma, Inc. is using its unique structure-guided platform to develop antiviral drugs. This graph highlights the potential value of their technology. It demonstrates how a cutting-edge scientific approach can enable a small team of scientists to create highly effective drugs with enormous commercial potential, especially in light of global viral threats.
%20in%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-virus&v=1772574327274 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma virus")
Profit per employee (in thousands of dollars) for the market as a whole
Cocrystal Pharma, Inc. is a biotechnology company developing antiviral drugs (e.g., for influenza, hepatitis C, and COVID-19). It is a clinical-stage R&D company. This chart reflects the investment intensity (costs) per scientist required to create and test new antiviral molecules.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772574327289 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Cocrystal Pharma Inc. (COCP)
Cocrystal Pharma is a clinical-stage biopharmaceutical company developing antiviral drugs. This graph, showing zero revenue per employee, is typical for the sector. It reflects investment in research. Success in development will lead to explosive growth in this metric.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Cocrystal-Pharma-Inc.-COCP&v=1772574327301 "Sales chart per company employee Cocrystal Pharma Inc. (COCP)")
Sales per employee in the market segment - Pharma virus
Cocrystal Pharma (COCP) is a biopharmaceutical company specializing in the development of antiviral drugs (e.g., for influenza, hepatitis C, and COVID-19) using its structural crystallography platform. This chart shows the average revenue per employee in the pharmaceutical segment. For COCP, which is in the R&D stage, comparison to this benchmark (zero) underscores their focus on science.
Sales per employee for the market as a whole
Cocrystal Pharma (COCP) is a clinical-stage biotech developing antiviral drugs (for influenza and hepatitis). They have no revenue. This metric is irrelevant. Their entire value lies in the potential of their scientific platform.
Short shares by company, segment and market as a whole
Shares shorted by company Cocrystal Pharma Inc. (COCP)
Cocrystal Pharma is a biotech company specializing in the development of antiviral drugs, including those for influenza and hepatitis C. This chart shows the bets on the failure of their developments. The bears believe their drug candidates will fail to prove effective in clinical trials, and the company will burn through all its capital.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Cocrystal-Pharma-Inc.-COCP&v=1772574327349 "Short Shares Chart for the Company Cocrystal Pharma Inc. (COCP)")
Shares shorted by market segment - Pharma virus
Cocrystal Pharma (COCP) is a biotech company that has been promising for years to develop a cure for influenza and hepatitis C. This chart shows the pessimism in the sector. The growing shorts in the industry are a bet that COCP will never release anything. Investors are tired of waiting and don't believe the company will be able to complete its perpetual preclinical development.
Shares shorted by the overall market
Cocrystal Pharma is a biotech focused on antiviral drugs (influenza, hepatitis). This chart reflects the overall market pessimism. Investors fear long R&D cycles. They see a company spending money on research and fear that competitors (Big Pharma) will bring their drugs to market faster.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Cocrystal Pharma Inc. (COCP)
This oscillator for Cocrystal Pharma is an indicator of pandemic fears. The company develops broad-spectrum antiviral drugs (for influenza, hepatitis, and COVID-19). "Overheating" (above 70) occurs during disease outbreaks or positive preclinical data. A lack of breaking news or trial failures quickly dampen investor enthusiasm, leading to "oversold" conditions.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Cocrystal-Pharma-Inc.-COCP&v=1772574327567 "RSI 14 indicator chart for the company's stock Cocrystal Pharma Inc. (COCP)")
RSI 14 Market Segment - Pharma virus
Cocrystal (COCP) is a "biotech" and a "virus hunter." Their "platform" (based on "structural" biology) "designs" small molecules against "flu," "COVID," and "norovirus." The "Pharma virus" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand: is COCP's growth due to their R&D, or is the entire biotech sector "overheated?"
RSI 14 for the overall market
Cocrystal Pharma (COCP) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast COCP (Cocrystal Pharma Inc.)
Cocrystal Pharma (COCP) is a biotech company developing antiviral drugs (including those for influenza and COVID-19). This chart shows the average 12-month forecast. It reflects analysts' speculative assessment of its scientific platform and the likelihood of success in clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-COCP-Cocrystal-Pharma-Inc.&v=1772574327645 "A chart showing analyst consensus forecasts for the expected stock price. COCP (Cocrystal Pharma Inc.)")
The difference between the consensus estimate and the actual stock price COCP (Cocrystal Pharma Inc.)
Cocrystal Pharma is a biotech company focused on developing antiviral drugs (pills) for the treatment of influenza, hepatitis C, and COVID-19. This chart shows how the current share price differs from the "fair" value predicted by analysts. It reflects their confidence in the company's R&D portfolio and technology.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-COCP-Cocrystal-Pharma-Inc.&v=1772574327678 "A chart showing the difference between the consensus forecast and the actual stock price. COCP (Cocrystal Pharma Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma virus
Cocrystal Pharma is a biotech company focused on developing antiviral drugs (for influenza, hepatitis, and COVID). This is risky R&D. This chart reflects analysts' overall expectations for the entire antiviral pharmaceutical sector. It shows whether experts believe there will be demand for new drugs after the pandemic.
Analysts' consensus forecast for the overall market share price
Cocrystal Pharma is a biotech company specializing in the development of antiviral drugs (for influenza, COVID-19, and hepatitis). This chart shows the overall market "risk appetite." For Cocrystal, a high-risk clinical-stage company, overall market optimism (as shown by the rising chart) is critical for attracting the capital needed to fund R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Cocrystal Pharma Inc.
Cocrystal Pharma is a biotech R&D company with an all-in-one focus on antiviral drugs. They are using their R&D platform to develop small molecules (tablets) against influenza, hepatitis, and COVID-19. This chart is a pure indicator of their R&D. It doesn't reflect revenue, but rather a speculative estimate of their (very risky) pipeline and their chances of success.
AKIMA Market Segment Index - Pharma virus
Cocrystal Pharma (COCP) is a biopharmaceutical company specializing in the development of antiviral drugs. They are using their platform to create small-molecule drugs against influenza, hepatitis C, and COVID-19. The chart shows the average index for the segment, helping investors assess how COCP's risks in this complex field compare to the average.
The AKIM Index for the overall market
Cocrystal Pharma is a biotech company using structural biology to develop antiviral drugs (for influenza, COVID-19, and norovirus). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this R&D story compares to overall economic trends in the infectious disease sector.
